CD274 and non-small cell lung carcinoma: This study used 2 independent cohorts of patients with NSCLC (cohort 1: 48 patients; mean [SD] age, 60 [13] years; 15 [31.2%] female; cohort 2: 50 patients; mean [SD] age, 58 [8] years; 15 [30.0%] female) to examine the correlation between bTMB estimated by NCC-GP150 and tTMB measured by WES and to identify the utility of bTMB estimated by NCC-GP150 in distinguishing patients who would benefit from anti–PD-1 and anti–PD-L1 therapy.